Search company, investor...

KAI Pharmaceuticals

Founded Year



Acquired | Acquired

Total Raised




About KAI Pharmaceuticals

KAI Pharmaceuticals is a privately held, venture-backed drug discovery and development company with preclinical and clinical programs in acute cardiovascular and other diseases representing unmet medical needs. The company has applied its core expertise in the biology of PKC to develop highly potent and selective inhibitors and activators for each of the PKC isozymes for the treatment of a broad array of human diseases. KAI has received Fast-Track designation from the FDA for its lead compound, KAI-9803, which has recently completed a Phase I/II clinical trial to assess safety and efficacy in treating reperfusion injury in acute myocardial infarction. In April 2012, KAI Pharmaceuticals was acquired by Amgen. The valuation of KAI Pharmaceuticals was $315 million.

Headquarters Location

270 Littlefield Avenue

South San Francisco, California, 94080,

United States


Missing: KAI Pharmaceuticals's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: KAI Pharmaceuticals's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

KAI Pharmaceuticals Patents

KAI Pharmaceuticals has filed 30 patents.

The 3 most popular patent topics include:

  • Biotechnology
  • Peptides
  • Proteins
patents chart

Application Date

Grant Date


Related Topics




Kidney diseases, Rare diseases, G protein coupled receptors, Transcription factors, Syndromes


Application Date


Grant Date



Related Topics

Kidney diseases, Rare diseases, G protein coupled receptors, Transcription factors, Syndromes



Latest KAI Pharmaceuticals News

Attralus Therapeutics Appoints Mark Timney as CEO and Expands Leadership Team with New Executives

Aug 26, 2021

Attralus, backed by venBio Partners, recruits new leadership team to support advancement of its pipeline to bring transformational pan-amyloid removal therapies to the systemic amyloidosis field May 10, 2021 07:00 AM Eastern Daylight Time SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )-- Attralus Therapeutics today announced the appointment of Mark Timney as the company’s Chief Executive Officer and a member of its Board of Directors. Timney brings to Attralus more than 30 years of leadership experience at publicly traded and global biopharmaceutical companies, including his most recent role as CEO of The Medicines Company (NASDAQ: MDCO) until its sale for $9.7 billion to Novartis AG (NYSE: NVS) which was completed in 2020. Timney joins Attralus to accelerate clinical development of its product pipeline and expand the company’s business plan. Spencer Guthrie, the co-founder who led the company during early development, will continue at Attralus as Chief Operating Officer. The company also expanded the Board of Directors with the appointment of Rahul Kakkar, MD as an independent director who brings 20 years of experience founding and building biotechnology companies and as a practicing physician. In addition, the company announced the appointment of four additional executives to its leadership team: Gregory Bell, MD, Chief Medical Officer; Glen Firestone, Chief Business Officer; Krishna Gorti, MD, Head of Corporate Development; and Michael Klein, PhD, Head of Chemistry, Manufacturing and Controls (CMC). Each of these executives brings more than 20 years of experience in the biopharmaceutical industry in their respective areas of expertise. “We are pleased to welcome Mark Timney as CEO of Attralus, as he brings a track record for delivering value for patients, health care systems and investors. His leadership will guide Attralus to realize the potential of its transformative therapies for systemic amyloidosis which address a wide range of unmet needs for patients with all forms of this disease,” said Richard Gaster, MD, PhD, Attralus Board member and Partner at venBio Partners. Mark Timney, Chief Executive Officer Mark Timney stated, “I am excited to lead Attralus, a company built on deep fundamental research in the field of amyloidosis with a strong commitment to delivering life-changing therapies for patients. I see an extraordinary opportunity for Attralus to advance novel pan-amyloid removal therapies that open the potential to treat and reverse disease in patients with all types of systemic amyloidosis. There are extensive, unmet medical needs that can be addressed by diagnosing and therapeutically removing toxic, disease-causing amyloid in patients with systemic amyloidosis. I look forward to working with the very talented team at Attralus to make a significant difference in the lives of these patients.” In leadership roles at publicly traded and global biopharmaceutical companies, Timney has successfully managed companies through stages of growth and transition, launched numerous breakthrough medicines, and led high-value strategic transactions. Most recently, Timney served as CEO and Board member of The Medicines Company where he led the company through late-stage clinical development and maximized the potential for inclisiran, a first-in-class siRNA cholesterol-lowering therapy. These actions increased shareholder return more than three-fold within one year and culminated in the company’s acquisition by Novartis. Previously, he held senior roles in biopharmaceutical companies that include Merck & Co., Purdue Pharmaceuticals, Zeneca Group, ICI Pharmaceuticals and Roussel Labs, and has led markets that include the United States, Japan, South Korea, Australia and New Zealand. Timney received a bachelor’s degree from Newcastle Polytechnic (now Northumbria University) in Newcastle in the United Kingdom. New Board Member Rahul Kakkar, MD, Independent Board Director: Dr. Kakkar is a biotech entrepreneur and physician-scientist with nearly 20 years of professional experience, spanning founding and building biotechnology companies, as well as working as a practicing physician. Most recently, he was Chief Executive Officer at Pandion Therapeutics, a company developing innovative modular therapeutics autoimmune and inflammatory diseases, which he led to reach the stage as a clinical-stage company and successfully completed an initial public offering prior to Pandion’s acquisition by Merck for $1.9 billion. Prior to joining Pandion, he served as an executive at Corvidia Therapeutics where he was a founder, Chief Medical Officer and Chief Strategy Officer, guiding the company from seed stage through Series B and its lead asset through clinical proof of concept. Corvidia was acquired by Novo Nordisk for $2.1 billion. Corvidia was a “spin-out” from AstraZeneca, where Dr. Kakkar had served as Director for Emerging Innovations, responsible for preclinical through Phase 2 clinical studies both for compounds within the AstraZeneca pipeline and in support of compound out-licensing efforts. He continues to practice medicine as Associate Physician at Brigham and Woman’s Hospital and is a Lecturer in Medicine at Harvard Medical School. Dr. Kakkar is dual-trained via the American Board of Internal Medicine Fast Track program in molecular biology and clinical cardiology, and he is a fellow of the American College of Cardiology. New Executive Leaders Attralus has appointed these veteran biopharmaceutical leaders who bring deep clinical, manufacturing and business expertise to support the company’s growth and clinical advancement of its pipeline. Gregory Bell, MD, Chief Medical Officer: Dr. Bell has extensive expertise in the development of investigational therapies, having recently served as Vice President, Safety Risk Management of the Immunology, Infectious Disease and Ophthalmology portfolio at Genentech. Previously, he was Senior Vice President, Development and Chief Medical Officer at KAI Pharmaceuticals where he led the global development of Parsabiv® until Amgen acquired KAI in 2012. Earlier in his career, Bell served as Vice President of Clinical Development, Biometrics and Clinical Operations at Abgenix with responsibilities across all clinical programs including Vectibix®; at Merck, he contributed to several products that received regulatory approval including Vioxx®, Etoricoxib® and Cancidas®. Prior to joining Attralus, Greg was Senior Vice President of Development at Global Blood Therapeutics. Glen Firestone, Chief Business Officer: Mr. Firestone has a distinguished 25-year career as an executive leader and has utilized his deep strategic and commercial expertise to build businesses, launch breakthrough therapies, improve patients’ lives and create value. Firestone recently led a consulting business advising biotech companies on corporate growth strategies, commercialization, product development, market access, and business development. Previously, he served as a strategic advisor to Valo Health and was Head of Commercialization at Tmunity Therapeutics. Earlier, Firestone spent 20 years as a commercial executive at Merck with responsibility for leading many global and U.S. franchises, including the cardiovascular business, launching innovative medicines, building blockbuster product portfolios, negotiating business development deals and building partnerships. Krishna Gorti, MD, Head of Corporate Development: Dr. Gorti has a rich and diverse background including roles in corporate development and investor relations, as an investment analyst covering biotechnology companies, as a physician trained in otolaryngology and head and neck surgery, and as a clinical and translational researcher. In his previous tenure with The Medicines Company, he served as Senior Vice President of Investor Relations and played an integral role in value-building initiatives, as well as working in earlier roles in business development and strategy. Prior to roles with biopharmaceutical companies, Gorti was a biotechnology industry equity research analyst with leading financial institutions, including JP Morgan, Piper Jaffray and Rodman & Renshaw. Michael Klein, PhD, Head of Chemistry, Manufacturing and Controls (CMC): Dr. Klein has more than 30 years of experience in the biotechnology industry, having spent his career working in various aspects of CMC development of therapeutic proteins, including monoclonal antibodies, Fc fusions, bispecific and multifunctional therapeutics. Most recently, Klein served as Vice President of Analytical Development at Nektar Therapeutics and was a member of the leadership team of the company’s Product Development and Manufacturing group. Previously, he was CMC scientific leader at Agenus, Atara Bio, Xencor, Protein Design Labs and Amgen. About Systemic Amyloidosis Systemic amyloidosis encompasses a diverse group of rare diseases that occur due to accumulation of toxic amyloid fibrils in tissues and organs, which is triggered by aberrant protein misfolding. These diseases are progressive, debilitating and often fatal. Systemic amyloidosis is significantly underdiagnosed due to low awareness, lack of specific symptoms, and no current disease-specific diagnostics. The two most common forms of systemic amyloidosis are transthyretin amyloidosis (ATTR) and amyloid light-chain (AL) amyloidosis. About Attralus Attralus is a clinical stage biopharmaceutical company focused on creating transformative medicines to improve the lives of patients with systemic amyloidosis. The company’s proprietary pan-amyloid removal (PAR) therapeutic product candidates are designed to directly bind to and remove toxic amyloid in organs and tissues. By targeting the universal disease-causing pathology in all systemic amyloidosis diseases, PAR therapeutics have the potential to treat and reverse disease in patients with all types and stages of systemic amyloidosis. Attralus was founded by scientific experts in the field of amyloidosis and is headquartered in South San Francisco, California. Contacts

KAI Pharmaceuticals Frequently Asked Questions (FAQ)

  • When was KAI Pharmaceuticals founded?

    KAI Pharmaceuticals was founded in 2002.

  • Where is KAI Pharmaceuticals's headquarters?

    KAI Pharmaceuticals's headquarters is located at 270 Littlefield Avenue, South San Francisco.

  • What is KAI Pharmaceuticals's latest funding round?

    KAI Pharmaceuticals's latest funding round is Acquired.

  • How much did KAI Pharmaceuticals raise?

    KAI Pharmaceuticals raised a total of $63M.

  • Who are the investors of KAI Pharmaceuticals?

    Investors of KAI Pharmaceuticals include Amgen, Skyline Ventures, Delphi Ventures, InterSouth Partners, Thomas Weisel Partners and 6 more.

  • Who are KAI Pharmaceuticals's competitors?

    Competitors of KAI Pharmaceuticals include Radius, Tetraphase Pharmaceuticals, Asteres, Vasopharm, Aegerion Pharmaceuticals, Eiger BioPharmaceuticals, Athenex, CoLucid Pharmaceuticals, Napo Pharmaceuticals, BioCardia and 31 more.

Compare KAI Pharmaceuticals to Competitors

Neuraltus Pharmaceuticals

Neuraltus Pharmaceuticals is a privately-held biopharmaceutical company dedicated to developing and commercializing innovative therapeutics that address critical unmet needs for patients and physicians in the treatment of neurodegenerative diseases. The Company is collaborating with global ALS specialists and seeking input from patient advocacy organizations to help inform the clinical development path and better understand the needs of people affected by the disease.

Intarcia Therapeutics

Intarcia Therapeutics is a biopharmaceutical company based in Boston, Massachusetts. Intarcia is engaged in the development of a pipeline of products for the proprietary Medici Drug Delivery System comprised of three technologies: A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, a matchstick-sized osmotic mini-pump that is placed under the dermal layer of skin to deliver a continuous and consistent flow of medication, and a placement technology including proprietary tools designed to provide an optimal user experience.


Humanetics is a clinical-stage pharmaceutical company engaged in developing and commercializing products to enhance human health and wellbeing in markets with urgent and unmet needs. It has a focus on radiation modulators for oncology, medical imaging, and medical countermeasure uses. The company develops BIO 300, a highly selective modulator of inflammation, cell cycle arrest, and DNA damage repair. Humanetics was founded in 1988 and is based in Minneapolis, Minnesota.

Quark Pharmaceuticals

Quark Pharmaceuticals is a development-stage pharmaceutical company discovering and developing RNA interference (RNAi)-based therapeutics.

Marillion Pharmaceuticals

Marillion Pharmaceuticals, Inc. - Marillion is developing clinical-stage drugs in oncology and oncology supportive care. 177Lu-AMBA is a targeted radiotherapeutic, with the low level radiation of lutetium that aims to utilize an receptor-based technology, and can serve as both a diagnostic and therapeutic agent. The targeting capability means that 177Lu-AMBA homes in on tumor cells and spares normal tissues. 177Lu-AMBA is being pursued initially to treat hormone-resistant prostate cancer, has been studied in a phase I trial in Europe. Marillion also is developing PilobucTM , buccal formulation of pilocarpine ,for the treatment of dry mouth, shown in clinical trials to effectively and conveniently deliver the drug with reduced side effects compared to other routes of administration.PilobucTM buccal formulation of pilocarpine has the potential to be a product in the xerostomia market. Marillion is preparing for phase II trials of the product candidate..

Radius Logo

Radius Health is a biopharmaceutical company focused on developing new therapeutics to treat osteoporosis and other women's health conditions. It is committed to the development of therapeutics for the osteoporosis market. The company's lead product candidate, BA058-SC, is in effect to reduce the risk of complications associated with osteoporosis, such as fractures and has a transdermal patch, BA058-TD, being developed as a short wear-time delivery vehicle intended to improve patient compliance with convenience and ease of use, as well as a product in development to treat symptoms associated with menopause. The company was founded in 2003 and is based in Boston, Massachusetts.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.